A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies.
Cancer-testis (CT) antigens/genes show restricted expression in normal tissues but widespread expression in many tumour types. This, coupled with their ability to induce cytotoxic T-lymphocyte responses, makes them attractive vaccine candidates. Following our identification of PASD1, we have used RT...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2010
|
| _version_ | 1826264283544027136 |
|---|---|
| author | Liggins, A Lim, S Soilleux, E Pulford, K Banham, A |
| author_facet | Liggins, A Lim, S Soilleux, E Pulford, K Banham, A |
| author_sort | Liggins, A |
| collection | OXFORD |
| description | Cancer-testis (CT) antigens/genes show restricted expression in normal tissues but widespread expression in many tumour types. This, coupled with their ability to induce cytotoxic T-lymphocyte responses, makes them attractive vaccine candidates. Following our identification of PASD1, we have used RT-PCR to analyse the mRNA expression profile of a large panel of CT genes in cell lines derived from haematological malignancies, and have studied Sp17 protein expression in the same cell lines and diffuse large B-cell lymphoma (DLBCL) biopsies. Our extensive analysis revealed multiple CT transcripts exhibiting widespread expression across cell lines derived from 21 B- and 4 T-cell malignancies. The broadest mRNA expression profiles were observed for the following eight CT genes: Sp17 (25/25), PRAME (25/25), CSAGE (24/25), PASD1 (22/25), CAGE/DDX53 (19/25), CTAGE1 (19/25), HAGE/DDX43 (16/25) and PLU-1/JARID1B (15/25). Cell lines derived from more aggressive lymphoma subtypes generally expressed CT transcripts at higher frequency. Sp17 protein was detected in a number of cell lines and in six of eleven (54.5%) DLBCL biopsies. Analysis of Sp17 protein expression, by immunohistochemistry and Western blotting, broadens the scope of this CT antigen as a potentially relevant clinical target in haematological malignancies. Further studies of protein expression are now needed to validate these antigens as vaccine candidates. |
| first_indexed | 2024-03-06T20:05:17Z |
| format | Journal article |
| id | oxford-uuid:28b4e1fc-138b-4c50-b621-0830f6efd3f4 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:05:17Z |
| publishDate | 2010 |
| record_format | dspace |
| spelling | oxford-uuid:28b4e1fc-138b-4c50-b621-0830f6efd3f42022-03-26T12:14:35ZA panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:28b4e1fc-138b-4c50-b621-0830f6efd3f4EnglishSymplectic Elements at Oxford2010Liggins, ALim, SSoilleux, EPulford, KBanham, ACancer-testis (CT) antigens/genes show restricted expression in normal tissues but widespread expression in many tumour types. This, coupled with their ability to induce cytotoxic T-lymphocyte responses, makes them attractive vaccine candidates. Following our identification of PASD1, we have used RT-PCR to analyse the mRNA expression profile of a large panel of CT genes in cell lines derived from haematological malignancies, and have studied Sp17 protein expression in the same cell lines and diffuse large B-cell lymphoma (DLBCL) biopsies. Our extensive analysis revealed multiple CT transcripts exhibiting widespread expression across cell lines derived from 21 B- and 4 T-cell malignancies. The broadest mRNA expression profiles were observed for the following eight CT genes: Sp17 (25/25), PRAME (25/25), CSAGE (24/25), PASD1 (22/25), CAGE/DDX53 (19/25), CTAGE1 (19/25), HAGE/DDX43 (16/25) and PLU-1/JARID1B (15/25). Cell lines derived from more aggressive lymphoma subtypes generally expressed CT transcripts at higher frequency. Sp17 protein was detected in a number of cell lines and in six of eleven (54.5%) DLBCL biopsies. Analysis of Sp17 protein expression, by immunohistochemistry and Western blotting, broadens the scope of this CT antigen as a potentially relevant clinical target in haematological malignancies. Further studies of protein expression are now needed to validate these antigens as vaccine candidates. |
| spellingShingle | Liggins, A Lim, S Soilleux, E Pulford, K Banham, A A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. |
| title | A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. |
| title_full | A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. |
| title_fullStr | A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. |
| title_full_unstemmed | A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. |
| title_short | A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. |
| title_sort | panel of cancer testis genes exhibiting broad spectrum expression in haematological malignancies |
| work_keys_str_mv | AT ligginsa apanelofcancertestisgenesexhibitingbroadspectrumexpressioninhaematologicalmalignancies AT lims apanelofcancertestisgenesexhibitingbroadspectrumexpressioninhaematologicalmalignancies AT soilleuxe apanelofcancertestisgenesexhibitingbroadspectrumexpressioninhaematologicalmalignancies AT pulfordk apanelofcancertestisgenesexhibitingbroadspectrumexpressioninhaematologicalmalignancies AT banhama apanelofcancertestisgenesexhibitingbroadspectrumexpressioninhaematologicalmalignancies AT ligginsa panelofcancertestisgenesexhibitingbroadspectrumexpressioninhaematologicalmalignancies AT lims panelofcancertestisgenesexhibitingbroadspectrumexpressioninhaematologicalmalignancies AT soilleuxe panelofcancertestisgenesexhibitingbroadspectrumexpressioninhaematologicalmalignancies AT pulfordk panelofcancertestisgenesexhibitingbroadspectrumexpressioninhaematologicalmalignancies AT banhama panelofcancertestisgenesexhibitingbroadspectrumexpressioninhaematologicalmalignancies |